Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.49 |
| ▸ | MAOB | P27338 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294324 | 0.94 | MAOB (0.51) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL7303830 | 0.90 | ACHE (0.55) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL7307720 | 0.90 | RAB9A (0.39) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL5617681 | 0.88 | MAOB (0.53) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL7295636 | 0.88 | MAOB (0.53) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL5618127 | 0.87 | MAOB (0.52) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL9135893 | 0.83 | RAB9A (0.39) | RAB9A | |
| SCHEMBL7301295 | 0.79 | ACHE (0.62) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL7294118 | 0.77 | ALDH1A1 (0.57) | ACHEMAOBALDH1A1POLBHSP90AA1 | |
| SCHEMBL7302328 | 0.77 | ACHE (0.56) | ACHEMAOBALDH1A1POLBHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| EP-0363796-B1 | HETEROCYCLICALLY SUBSTITUTED ALKOXYCOUMARINES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL AGENTS CONTAINING SAME | BASF Aktiengesellschaft (DE) | 1993-08-11 | — | — | EP | disclosed |
| US-5227392-A | Monoamine oxidase inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| US-5073563-A | Enzyme inhibitors, CNS | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-17 | — | — | US | disclosed |
| EP-0363796-A1 | Heterocyclically substituted alkoxycoumarines, method for their preparation and therapeutical agents containing same | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | ACHE 639/4885MAOB 1/4885ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.